CA3240577A1 - Methods of treating hypertension by periodic suppression of aldosterone synthase - Google Patents

Methods of treating hypertension by periodic suppression of aldosterone synthase Download PDF

Info

Publication number
CA3240577A1
CA3240577A1 CA3240577A CA3240577A CA3240577A1 CA 3240577 A1 CA3240577 A1 CA 3240577A1 CA 3240577 A CA3240577 A CA 3240577A CA 3240577 A CA3240577 A CA 3240577A CA 3240577 A1 CA3240577 A1 CA 3240577A1
Authority
CA
Canada
Prior art keywords
subject
cyp
beta hydroxylase
hydroxylase inhibitor
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3240577A
Other languages
English (en)
French (fr)
Inventor
David Rodman
Brian Taylor SLINGSBY
Jon CONGLETON
Hidetoshi Shimizu
Yoshiyasu OTA
Madori ORIHASHI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Mineralys Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3240577A1 publication Critical patent/CA3240577A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3240577A 2022-01-19 2023-01-19 Methods of treating hypertension by periodic suppression of aldosterone synthase Pending CA3240577A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263300967P 2022-01-19 2022-01-19
US63/300,967 2022-01-19
US202263400301P 2022-08-23 2022-08-23
US63/400,301 2022-08-23
PCT/IB2023/050444 WO2023139506A1 (en) 2022-01-19 2023-01-19 Methods of treating hypertension by periodic suppression of aldosterone synthase

Publications (1)

Publication Number Publication Date
CA3240577A1 true CA3240577A1 (en) 2023-07-27

Family

ID=87347916

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3240577A Pending CA3240577A1 (en) 2022-01-19 2023-01-19 Methods of treating hypertension by periodic suppression of aldosterone synthase

Country Status (7)

Country Link
US (1) US20250099475A1 (cg-RX-API-DMAC7.html)
EP (1) EP4466021A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025503015A (cg-RX-API-DMAC7.html)
KR (1) KR20240140102A (cg-RX-API-DMAC7.html)
CA (1) CA3240577A1 (cg-RX-API-DMAC7.html)
TW (1) TW202339758A (cg-RX-API-DMAC7.html)
WO (1) WO2023139506A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4577217A4 (en) * 2022-08-23 2026-08-12 Mineralys Therapeutics Inc METHODS OF TREATING HYPERTENSION WITH A COMBINATION OF AN ALDOSTERONE SYNTHASE INHIBITOR AND A DIURETIC
KR20250053914A (ko) * 2022-08-23 2025-04-22 미네랄리스 테라퓨틱스, 아이엔씨. 비만 대상체에서 고혈압을 치료하는 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550750B2 (en) * 2012-10-05 2017-01-24 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitors
WO2014179186A1 (en) * 2013-04-30 2014-11-06 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
US20240009201A1 (en) * 2020-10-26 2024-01-11 Mineralys Therapeutics, Inc. Cyp11b2 beta hydroxylase inhibitors for hypertension

Also Published As

Publication number Publication date
KR20240140102A (ko) 2024-09-24
EP4466021A1 (en) 2024-11-27
WO2023139506A1 (en) 2023-07-27
US20250099475A1 (en) 2025-03-27
TW202339758A (zh) 2023-10-16
JP2025503015A (ja) 2025-01-30
EP4466021A4 (en) 2026-01-14

Similar Documents

Publication Publication Date Title
Weir et al. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors
Khder et al. Sacubitril/valsartan (LCZ696) in heart failure
Luther et al. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II–induced cardiac, renal, and vascular injury
US9387249B2 (en) Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
JP7814368B2 (ja) 慢性腎疾患の治療のためのジボテンタン及びダパグリフロジンの組み合わせ
Amar et al. Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism
US20250099475A1 (en) Methods of treating hypertension by periodic suppression of aldosterone synthase
MXPA02010091A (es) Novedoso uso medico de inhibidores de sintasa de aldosterona solos o en combinacion con antagonistas del receptor at-1.
Tylicki et al. The enhanced renin-angiotensin-aldosteron system pharmacological blockade-which is the best?
Ubaid‐Girioli et al. Aldosterone escape with diuretic or angiotensin‐converting enzyme inhibitor/angiotensin II receptor blocker combination therapy in patients with mild to moderate hypertension
Theodor et al. Absolute bioavailability of moxonidine
CN110785168A (zh) 用于预防或治疗猫的全身性疾病的血管收缩素ii受体拮抗剂
Plosker et al. Telmisartan/hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension
US20260053811A1 (en) Methods of treating hypertension in obese subjects
US20260053812A1 (en) Methods of treating hypertension with a combination of an aldosterone synthase inhibitor and a diuretic
Elliott et al. Pharmacology of antihypertensive drugs
WO2025024488A2 (en) Methods of treating hypertension with a combination of lorundrostat and two or more anti-hypertensive medications
EP1842543A1 (en) Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
TW202510887A (zh) 以勞倫卓司他(lorundrostat)或勞倫卓司他與sglt2抑制劑之組合治療慢性腎臟病(ckd)或ckd與高血壓之方法
EA044411B1 (ru) Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250117

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250117

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250117

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260112

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260112